<DOC>
	<DOC>NCT01390415</DOC>
	<brief_summary>This study will evaluate whether losartan protects the kidney in hypertensive Type II diabetic participants with microalbuminuria.</brief_summary>
	<brief_title>A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Diabetes mellitus Hypertension and has received losartan 50 mg or losartan 100 mg for at least 6 months Microalbuminuria (defined as microalbuminuria &gt; 30 mg/g and &lt; 300 mg/g by spot urine test) Serum creatinine ≤1.5 mg/dL for men and ≤1.4mg/dL for women Urinalysis with white blood cells (WBC) &lt;5 cells per high power field Results of hemoglobin A1c (HbA1c), fasting blood glucose, serum creatinine, urine albumin/urine creatinine ratio and urinary analysis tests at baseline and 6 months after initiating the losartan therapy are available Medical history and comorbidities (if available) listed in medical records Prescription information of antihypertensive regimen of losartan 50 mg or 100 mg available Exclusion criteria: Treated with angiotensinconverting enzyme (ACE) inhibitors or angiotensinreceptor blockers (ARB) before initiated treatment with losartan 50 mg or losartan 100 mg Enrollment in another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>